{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    19,
    20,
    21,
    22,
    23,
    24,
    25
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "LY900018",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Single 3-mg dose of nasal glucagon powder administered by study site personnel using a single-use nasal dosing device."
      },
      {
        "id": "arm_2",
        "name": "IMG (GlucaGen)",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Single 1-mg dose of intramuscular glucagon administered by study site personnel via injection following reconstitution."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_1",
        "epochId": "epoch_6",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_11",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_11"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_12",
        "armId": "arm_2",
        "epochId": "epoch_6",
        "elementIds": [
          "elem_12"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Type 1 Diabetes Mellitus (T1DM)",
        "instanceType": "StudyCohort",
        "characteristic": "Japanese patients diagnosed with T1DM on daily insulin therapy for at least 1 year."
      },
      {
        "id": "cohort_2",
        "name": "Type 2 Diabetes Mellitus (T2DM)",
        "instanceType": "StudyCohort",
        "characteristic": "Japanese patients diagnosed with T2DM on daily insulin therapy for at least 1 year."
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "LY900018 - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY900018 during Screening"
      },
      {
        "id": "elem_2",
        "name": "LY900018 - Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY900018 during Period 1"
      },
      {
        "id": "elem_3",
        "name": "LY900018 - Washout",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY900018 during Washout"
      },
      {
        "id": "elem_4",
        "name": "LY900018 - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY900018 during Period 2"
      },
      {
        "id": "elem_5",
        "name": "LY900018 - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY900018 during Follow-up"
      },
      {
        "id": "elem_6",
        "name": "LY900018 - Additional Follow-up for TE ADA",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY900018 during Additional Follow-up for TE ADA"
      },
      {
        "id": "elem_7",
        "name": "IMG (GlucaGen) - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for IMG (GlucaGen) during Screening"
      },
      {
        "id": "elem_8",
        "name": "IMG (GlucaGen) - Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for IMG (GlucaGen) during Period 1"
      },
      {
        "id": "elem_9",
        "name": "IMG (GlucaGen) - Washout",
        "instanceType": "StudyElement",
        "description": "Treatment period for IMG (GlucaGen) during Washout"
      },
      {
        "id": "elem_10",
        "name": "IMG (GlucaGen) - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for IMG (GlucaGen) during Period 2"
      },
      {
        "id": "elem_11",
        "name": "IMG (GlucaGen) - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for IMG (GlucaGen) during Follow-up"
      },
      {
        "id": "elem_12",
        "name": "IMG (GlucaGen) - Additional Follow-up for TE ADA",
        "instanceType": "StudyElement",
        "description": "Treatment period for IMG (GlucaGen) during Additional Follow-up for TE ADA"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 12,
      "cohortCount": 2,
      "elementCount": 12
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Endocrinology",
        "Diabetes Mellitus"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": []
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Endocrinology",
        "Diabetes Mellitus"
      ]
    },
    "arms": [
      {
        "name": "LY900018",
        "type": "Experimental Arm",
        "description": "Single 3-mg dose of nasal glucagon powder administered by study site personnel using a single-use nasal dosing device.",
        "isTitration": false
      },
      {
        "name": "IMG (GlucaGen)",
        "type": "Active Comparator",
        "description": "Single 1-mg dose of intramuscular glucagon administered by study site personnel via injection following reconstitution.",
        "isTitration": false
      }
    ],
    "cohorts": [
      {
        "name": "Type 1 Diabetes Mellitus (T1DM)",
        "characteristic": "Japanese patients diagnosed with T1DM on daily insulin therapy for at least 1 year."
      },
      {
        "name": "Type 2 Diabetes Mellitus (T2DM)",
        "characteristic": "Japanese patients diagnosed with T2DM on daily insulin therapy for at least 1 year."
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Within 28 days prior to enrollment."
      },
      {
        "name": "Period 1",
        "description": "First treatment period where patients receive either LY900018 or IMG following insulin-induced hypoglycemia."
      },
      {
        "name": "Washout",
        "description": "3 to 14 days between Period 1 and Period 2."
      },
      {
        "name": "Period 2",
        "description": "Second treatment period where patients receive the alternate treatment from Period 1."
      },
      {
        "name": "Follow-up",
        "description": "26 to 30 days after the last study treatment."
      },
      {
        "name": "Additional Follow-up for TE ADA",
        "description": "Follow-up for treatment-emergent anti-drug antibodies if required."
      }
    ]
  }
}